Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104782523 | 10478252 | 3 | F | 20140710 | 20160801 | 20140926 | 20160805 | EXP | IL-009507513-1409ISR005235 | MERCK | 67.00 | YR | M | Y | 0.00000 | 20160805 | CN | GB | IL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104782523 | 10478252 | 1 | PS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | 200 MG, BID | 42400 | MG | Y | 20903 | 200 | MG | CAPSULE | BID | |||
| 104782523 | 10478252 | 2 | SS | BOCEPREVIR | BOCEPREVIR | 1 | Oral | 200 MG, TID | 63600 | MG | Y | 0 | 200 | MG | CAPSULE | TID | |||
| 104782523 | 10478252 | 3 | SS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Subcutaneous | 180 MICROGRAM, QW | 2896.071 | UG | Y | 0 | 180 | UG | /wk | ||||
| 104782523 | 10478252 | 4 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 100 MG, QD | U | 0 | 100 | MG | TABLET | QD | |||||
| 104782523 | 10478252 | 5 | C | EXFORGE | AMLODIPINE BESYLATEVALSARTAN | 1 | 1 DF, QD | U | 0 | 1 | DF | QD | |||||||
| 104782523 | 10478252 | 6 | C | GLUCERNA | AMINO ACIDSDEXTROSEELECTROLYTES NOSSOYBEAN OILVITAMINS | 1 | Oral | 240 ML, QD, DAILY DOSE ALSO REPORTED AS 240 MG | U | 0 | 240 | ML | QD | ||||||
| 104782523 | 10478252 | 7 | C | AMARYL | GLIMEPIRIDE | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 104782523 | 10478252 | 8 | C | ATENOLOL. | ATENOLOL | 1 | UNK | U | 0 | ||||||||||
| 104782523 | 10478252 | 9 | C | EUTHYROX | LEVOTHYROXINE SODIUM | 1 | UNK | U | 0 | ||||||||||
| 104782523 | 10478252 | 10 | C | FERROGRAD FOLIC | 2 | UNK | U | 0 | |||||||||||
| 104782523 | 10478252 | 11 | C | OMEPRADEX | OMEPRAZOLE | 1 | UNK | U | 0 | ||||||||||
| 104782523 | 10478252 | 12 | C | TAMSULIN | 2 | UNK | U | 0 | |||||||||||
| 104782523 | 10478252 | 13 | C | cyanocobalamin (+) folic acid (+) pyridoxine hydrochloride | 2 | UNK | U | 0 | |||||||||||
| 104782523 | 10478252 | 14 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 40 MG, QD | U | 0 | 40 | MG | TABLET | QD | ||||||
| 104782523 | 10478252 | 15 | C | JANUET | METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE | 1 | Oral | 2 DF, QD | U | 0 | 2 | DF | FILM-COATED TABLET | QD | |||||
| 104782523 | 10478252 | 16 | C | EPOETIN BETA | ERYTHROPOIETIN | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 104782523 | 10478252 | 1 | Hepatitis C |
| 104782523 | 10478252 | 2 | Hepatitis C |
| 104782523 | 10478252 | 3 | Hepatitis C |
| 104782523 | 10478252 | 6 | Nutritional supplementation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 104782523 | 10478252 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 104782523 | 10478252 | Anaemia | |
| 104782523 | 10478252 | Bacteraemia | |
| 104782523 | 10478252 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 104782523 | 10478252 | 1 | 20140516 | 20140904 | 0 | |
| 104782523 | 10478252 | 2 | 20140516 | 20140904 | 0 | |
| 104782523 | 10478252 | 3 | 20140516 | 20140904 | 0 |